Posted by Michael Wonder on 24 Jul 2021
Dalvance (dalbavancin) receives FDA approval to treat acute bacterial skin and skin structure infections in paediatric patients
23 July 2021 - Dalvance is the first and only single dose infusion to treat acute bacterial skin and skin structure infections (ABSSSI) in paediatric patients from birth.
AbbVie today announced that the U.S. FDA approved Dalvance (dalbavancin) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in paediatric patients from birth.
Dalvance is the first single dose option administered as a 30 minute intravenous infusion for the treatment of ABSSSI caused by designated susceptible Gram-positive bacteria in paediatric patients, including infections caused by methicillin-resistant Staphylococcus aureus.
